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SCH 48973 is a novel molecule with potent, selective, antienterovirus activity. In assays of the cytopathic
effect against five picornaviruses, SCH 48973 had antiviral activity (50% inhibitory concentrations [IC50s]) of
0.02 to 0.11 mg/ml, with no detectable cytotoxicity at 50 mg/ml. SCH 48973 inhibited 80% of 154 recent human
enterovirus isolates at an IC50 of 0.9 mg/ml. The antiviral activity of SCH 48973 is derived from its specific
interaction with viral capsid, as confirmed by competition binding studies. The affinity constant (Ki) for SCH
48973 binding to poliovirus was 8.85 3 1028 M. In kinetic studies, a maximum of approximately 44 molecules
of SCH 48973 were bound to poliovirus capsid. SCH 48973 demonstrated efficacy in a murine poliovirus model
of enterovirus disease. SCH 48973 increased the survival of infected mice when it was administered orally at
dosages of 3 to 20 mg/kg of body weight/day. Oral administration of SCH 48973 also reduced viral titers in the
brains of infected mice. On the basis of its in vitro and in vivo profiles, SCH 48973 represents a potential
candidate for therapeutic intervention against enterovirus infections.
The Picornaviridae family contains three groups of human
pathogenic viruses: enteroviruses, rhinoviruses, and hepatitis A
virus. These positive-strand RNA viruses share a common
three-dimensional capsid structure which has been determined
from the X-ray crystallization of human rhinovirus type 14
(HRV-14), HRV-1A, HRV-3, HRV-16, poliovirus type 1, poliovirus type 3, and coxsackievirus type B3 (13, 21, 25, 30, 32,
35, 40). The capsid, which encapsulates the viral RNA, is composed of 60 promoters, each of which contains one copy of the
viral proteins VP1, VP2, VP3, and VP4. A significant feature
on the viral capsid is the “canyon” formed by the junctions of
VP1 and VP3. The canyon serves as the site for binding to the
viral cellular receptor (e.g., ICAM-1 for HRV-14) (17, 42, 44).
Underneath the canyon, within the VP1 protein, lies a hydrophobic cavity which is accessible through a pore in the canyon
floor. The hydrophobic cavity is the drug-binding site of a
number of diverse chemical structures that inhibit viral attachment and/or uncoating (2, 8, 11, 12, 14, 22, 24, 27, 33, 35, 37,
47). X-ray crystallography of drug-virus complexes confirms
the specific binding of these inhibitors (4, 7, 49) and has allowed for the chemical synthetic design of newer, more potent
compounds. Some capsid inhibitors have been investigated in
clinical studies (1, 5, 18, 41, 46). However, to date none have
been approved for use against diseases caused by rhinoviruses
or enteroviruses.
The compound described here, SCH 48973, is a member of
the SCH 47802 series of capsid-binding molecules (8). SCH
48973 is a potent, selective, antienterovirus molecule with in
vitro and in vivo activities.

Source of viruses. Enteroviruses representing the 15 most commonly isolated
immunotypes in the United States were obtained from M. Pallansch, Centers for
Disease Control and Prevention (CDC), Atlanta, Ga., or were collected by John
Modlin, Darmouth Medical School. Laboratory strains of enteroviruses were
obtained from the American Type Culture Collection, H. Rotbart (University of
Colorado Health Sciences Center, Denver), and C. Gauntt (University of Texas
Health Sciences Center, San Antonio). Poliovirus and coxsackievirus were propagated in HeLa cells, while RD and BGMK cells were used to propagate echoviruses and enteroviruses. The propagation of all viruses was done in Eagle’s
modified minimal essential medium (EMEM) with 1% fetal calf serum (FCS).
Virus working stocks were prepared by standard procedures (39, 45).
CPE assay. The cytopathic effect (CPE) assay was used to determine the
antiviral activity (50% inhibitory concentration [IC50]), the cytotoxic activity
(50% lethal concentration [LC50]), and the therapeutic indices (cytotoxic LC50/
antiviral IC50) of SCH 48973. The test compound and viruses were premixed for
45 min at 22°C and were used to infect cells (multiplicity of infection 5 1.0) in
96-well tissue culture plates (Falcon 3075; Laboratory Disposable Products,
North Haledon, N.J.). Following a 45-min incubation (37°C), the culture fluid
was aspirated and the monolayers were washed. EMEM with 1% FCS containing
the compound at the same concentration used for the preincubation step was
added, and incubation was continued for 18 to 24 h prior to measuring cellular
viability with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT formazan; Sigma Chemical Co.) (29). Uninfected cells were treated with
compound in the same assay to determine the LC50.
Plaque assay. A plaque reduction assay was used to evaluate the activity of
SCH 48973 against a spectrum of viruses from the enterovirus family. The assay
for coxsackieviruses was performed with HeLa cells, while RD cells were used for
the majority of echoviruses and all enteroviruses. Some assays for echoviruses
used BGMK cells. The assay was performed as described previously (8, 37).
Briefly, 150 PFU of virus was mixed with test compound (0.0001 to 50 mg/ml in
1% dimethyl sulfoxide) in EMEM with 1% FCS for 45 min, and the mixture was
added to monolayers of appropriate cells. After 45 min at 33°C, the inoculum and
compound mixture were aspirated, and the cells were washed and incubated with
a methyl cell overlay for 2 to 3 days without further addition of compound (37).
The number of PFU was determined at each concentration and was plotted as a
percentage of that for the control monolayers.
Radiolabelling of virus and viral purification. Virus was radiolabelled with
[3H]uridine and was purified by two consecutive rate zonal sedimentations in 30
to 70% sucrose gradients before pelleting (38).
Measurement of virus-bound SCH 48973. Purified poliovirus type 2 (2.47 3
1013 particles, as determined by optical density) was mixed with 1.150 pM
3
[ H]SCH 48973 (specific activity, 572.4 mCi/mg). It was assumed that SCH 48973
binds to noninfectious viral particles to the same extent as it binds to infectious
viral particles (particle/PFU ratio, 235:1). The mixture was incubated at 22°C for
prescribed times to allow SCH 48973 to bind to virus. Virus-bound and free SCH
48973 were separated by sedimentation in Sephadex G-50 NICK spin columns
(fine grade; Pharmacia, Piscataway, N.J.) in TNE buffer (0.02 M Trizma, 0.5 M
NaCl, 0.002 M EDTA [pH 7.2]) at 500 3 g for 5 min. The eluant was assayed for

MATERIALS AND METHODS
Antipicornaviral molecules. SCH 48973 (Fig. 1) was synthesized at the Schering-Plough Research Institute (16).

* Corresponding author. Mailing address: Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033.
Phone: (908) 298-3043. Fax: (908) 298-3918.
† Present address: Shaman Pharmaceuticals Inc., South San Francisco, CA 94080.
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FIG. 1. Structure of SCH 48973.

radioactivity by liquid scintillation counting. The number of virion-bound SCH
48973 molecules was calculated by using the total disintegrations per minute
recovered in the eluant and the specific activity of the [3H]SCH 48973 preparation. In parallel studies, a 90% recovery of purified 3H-labelled virions and PFU
was observed and was used to correct for the loss of virus attributed to experimental procedures.
Determination of the affinity constant for SCH 48973 binding to virus. The
affinity constant for SCH 48973 binding to poliovirus type 2 was determined by
competition binding between [3H]SCH 48973 and unradiolabelled SCH 48973.
The approach assumed that binding is equivalent for infectious and noninfectious viral particles and that [3H]SCH 48973 and unlabelled SCH 48973 possess
equivalent binding affinities. The protocol used for competition binding was that
described by Bennett (6). Briefly, 2.47 3 1013 particles of poliovirus type 2, 1.15
pmol of [3H]SCH 48973, and concentrations of 1021 to 1029M SCH 48973 were
incubated for 3 h (22°C). TNE buffer (200 ml) was added, the contents were
mixed, and the reaction mixtures were loaded onto a Sephadex G-50 NICK spin
column to separate virion-bound and unbound SCH 48973. The eluant, which
contained virus–[3H]SCH 48973 complexes, was collected, and the radioactivity
was directly counted. Results were plotted as the percentage of bound radioactivity versus the concentration of unlabelled SCH 48973.
Evaluation of SCH 48973 activity in animals. Studies with mice were performed as recommended elsewhere (30a). Groups of 15 to 25 male mice (weight,
16 to 20 g; Harlan Sprague-Dawley) were infected intracranially with poliovirus
type 2 (23). Treatment with SCH 48973 was by oral gavage (0.3 ml in corn oil).
Survival was monitored daily for 21 days. Results were evaluated for statistical
significance by chi-square analysis (10), and protection was considered to be
significant if the results met a probability of p ,0.05 for at least 5 days during the
study compared to the results for the placebo-treated group.
Recovery of virus from murine brain. Mice were infected with poliovirus type
2 (520 PFU) and were treated (beginning either 6 or 24 h after infection) with
SCH 48973 at 20 mg/kg of body weight/day (administered in four 5-mg/kg doses
every 6 h). Forty-eight hours after infection, the brains were removed from
euthanized mice and were frozen immediately in a methanol-dry ice bath. Tissues were weighed and homogenized for 1 min in dilution medium (EMEM with
1% FCS). After two cycles of freeze-thawing (methanol-dry ice bath), the tissues
were centrifuged at 5,000 3 g for 10 min. The aqueous layer was removed from
the pellet, and virus was quantitated by plaque assay.

RESULTS
CPE assay. The antiviral activity of SCH 48973 determined
by an MTT-based CPE assay against five viruses of the enterovirus group demonstrates that SCH 48973 is a potent antiviral
agent (Table 1). Against poliovirus type 2, coxsackievirus group
A9, and three echovirus immunotypes, SCH 48973 has antiviral IC50s ranging from 0.02 to 0.11 mg/ml. The lack of cytotoxicity at the highest concentration tested (50 mg/ml) indicates
that the antiviral activity is not due to adverse effects on cells.
Spectrum of activity against enteroviruses. Surveillance data
from the CDC indicate that 15 serotypes account for 65 to 89%
of the enterovirus isolates recovered in a given year in the
United States: echovirus types 3, 4, 5, 6, 7, 9, 11, 24, and 30;
coxsackievirus group A9; and coxsackievirus groups B1, B2,
B3, B4, and B5 (43). To determine the spectrum of activity of
SCH 48973, 154 recent human isolates representing the 15
common enterovirus serotypes were tested by plaque reduction assay. Sixty-one isolates were collected by the CDC in the
years 1990 to 1994. Ninety-three isolates were collected at
Johns Hopkins University in the years 1986 to 1990.
The antiviral activities of SCH 48973 against the 154 isolates
are presented in Fig. 2. SCH 48973 inhibited 80% of the immunotypes at an IC50 of 0.9 mg/ml. The median IC50 for 11 of
13 immunotypes was less than 1 mg/ml. Too few isolates of
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echovirus types 9 and 24 were tested to obtain an accurate
representation of the median IC50. The fact that SCH 48973
demonstrates potent inhibition against viruses plaqued on
three different cell lines (i.e., HeLa, RD, and BGMK) indicates
that the antiviral activity of the compound is not cell type
dependent. Cytotoxicity assays with MTT endpoints, performed with HeLa, RD, and BGMK cells in a manner similar
to that for the plaque assay, indicate that SCH 48973 possesses
antiviral activity in the absence of significant cytotoxicity (data
not shown).
Relation between enterovirus disease and antiviral activity.
Of the 154 viruses representing the 15 most common immunotypes, 44 isolates were from undiagnosed individuals or patients with enterovirus diseases not associated with the central
nervous system. The remaining viruses (71%; 110 of 154) were
isolated from patients diagnosed with aseptic meningitis and/or
meningoencephalitis. The average IC50 of SCH 48973 for these
110 viruses was 0.98 mg/ml. Ninety-three of these 110 isolates
were collected at Johns Hopkins University in the years 1985 to
1990, and the site from which the virus was recovered was
recorded. The site of recovery for the remaining 17 isolates was
unknown. Of the 93 viruses from patients with aseptic meningitis and/or meningoencephalitis, 47% were from the cerebrospinal fluid, while the remaining viruses were from the throat,
rectum, or urine. The historical frequency of enterovirus isolation in asymptomatic individuals is 3%, suggesting that viruses from non-central nervous system sites likely represent
the causative agent of disease (27a).
Specificity. SCH 48973 exerts its antiviral effect exclusively
against members of the picornavirus family. SCH 48973 is
inactive against herpes simplex virus type 1 and type 2, influenza virus A, human immunodeficiency virus type 1, adenovirus type 5, human rotavirus type 1, respiratory syncytial virus,
measles virus, Semliki Forest virus, simian virus 40, and vaccinia virus (data not shown).
Binding kinetics of SCH 48973. SCH 48973 was identified in
an assay designed to detect compounds which stabilize poliovirus to heat inactivation. Consistent with its ability to stabilize
poliovirus to heat inactivation, SCH 48973 is not virucidal
(data not shown), a characteristic shared by other members of
the SCH 47802 series (8). Data for other capsid inhibitors
indicate that the ability to thermally stabilize picornaviruses is
an independent but related measure of compound binding to
viral capsid (3). To confirm the specific binding of SCH 48973
and to determine the number of molecules that interact with
the capsid, the binding of [3H]SCH 48973 to purified poliovirus
type 2 particles was studied. The association of [3H]SCH 48973
with viral particles was observed after the separation of free
and bound molecules by sedimentation (Fig. 3). At maximum
binding (3 h), 44.83 6 5.08 molecules of SCH 48973 were

TABLE 1. Antiviral and cytotoxic activities of SCH 48973a
Virus

Antiviral activity
(IC50 [mg/ml])

Cytotoxic activity
(LC50 [mg/ml])

Poliovirus type 2
Coxsackievirus group A9
Echovirus type 4
Echovirus type 6
Echovirus type 11

0.08 6 0.04
0.09 6 0.07
0.11 6 0.09
0.03 6 0.005
0.02 6 0.01

.50.0
.50.0
.50.0
.50.0
.50.0

a
Data represent the means of at least four experiments and are expressed as
the means and standard errors. HeLa cells were used for the analysis of poliovirus type 2 and coxsackievirus group A9. BGMK cells were used for the analysis
of echoviruses. Poliovirus type 2 and coxsackievirus group A9 were from the
American Type Culture Collection. Echoviruses were from M. Pallansch, CDC.
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FIG. 2. Activity of SCH 48973 against recent human isolates of 15 immunotypes of enteroviruses. Open circles represent samples collected by the CDC, while closed
circles represent samples collected at Johns Hopkins University.

bound per viral particle. On the basis of the number of VP1
hydrophobic pockets per viral capsid and assuming a ratio of
one molecule per pocket, the theoretical maximum number of
capsid-binding molecules that can bind is 60. These findings
are consistent with the binding of SCH 48973 within the VP1
hydrophobic pocket.
Affinity of SCH 48973 for poliovirus type 2. The results of
competition binding studies are presented in Fig. 4. The IC50,
which represents an estimation of the affinity constant (Ki) (6)
for SCH 48973 binding to poliovirus type 2, was 8.85 3 1028
M. Nonspecific binding of SCH 48973 to poliovirus type 2
particles was 3.79% and was determined from the binding of
[3H]SCH 48973 in the presence of a 2 3 106-fold excess of
unlabelled SCH 48973 (Fig. 4).
Therapeutic efficacy of SCH 48973 in a poliovirus type 2
infection model. Figure 5 presents the results of efficacy studies
with SCH 48973 at three dosages (3 to 20 mg/kg/day) in poliovirus type 2-infected mice. In these studies, SCH 48973 was
administered therapeutically (3.5 h postinfection), and the total daily dosage was divided into three individual doses. SCH
48973 statistically increased survival at dosages of 3, 10, and 20
mg/kg/day compared to the survival rate for placebo-treated
animals (P # 0.05). The degree of efficacy among dosages was
not significantly different. Uninfected animals treated with
SCH 48973 demonstrated no loss of weight and there was no
mortality throughout this study or in other studies, including
those in which SCH 48973 was administered at dosages of 90
mg/kg/day for 21 days (data not shown).
Reduction of virus in mouse brains by SCH 48973. For mice
infected with poliovirus type 2 and treated (beginning either 6
or 24 h after infection) with SCH 48973 at 20 mg/kg/day, there
was a significant reduction (1 to 2 logs) in the titer of virus
recovered from the brains 2 days after infection (Table 2). The
difference between the two regimens (6 and 24 h) was not
significant. When brains from noninfected, SCH 48973-treated
mice were removed, homogenized, diluted, and inoculated in
vitro with known quantities of virus, no reduction of viral
plaques compared to the input inoculum was observed (data

not shown). These results indicate that the reduction in viral
load in brains is due to a direct effect of SCH 48973 in vivo and
not due to compound carryover into the tissue culture system.
DISCUSSION
SCH 48973 has potent in vitro activity against viruses of the
enterovirus family, as demonstrated in CPE and plaque reduction assays. Antiviral testing against viruses of the 15 most

FIG. 3. Binding kinetics of SCH 48973 to poliovirus type 2. [3H]SCH 48973
was allowed to bind to poliovirus particles at 22°C for the indicated times prior
to separating bound and free [3H]SCH 48973. The results represent means and
standard errors of two studies, each with three replicate samples per time point.
A decrease in the optical density at 280 nm was observed at the 4-h time point,
suggesting that the decrease in the number of bound molecules was due to
precipitation of viral particles.

VOL. 41, 1997

FIG. 4. The Ki for SCH 48973 binding to poliovirus type 2 was determined in
competition binding studies with [3H]SCH 48973. Incubation was performed
until equilibrium was reached (3 h at 22°C). The results represent means 6
standard errors of two different studies, each with three replicates per concentration.

commonly isolated enterovirus serotypes indicates that SCH
48973 inhibits 80% of the immunotypes (154 viruses) at an
IC50 of 0.9 mg/ml, a concentration that is within the levels of
the molecule achievable in plasma after oral dosing in higher
animals (data not shown). SCH 48973 demonstrates similar
activity against other enteroviruses which are not common in
the United States but which are widespread throughout the
world. For example, the concentration of SCH 48973 showing
activity against five strains of poliovirus type 1 (causative agent
of poliomyelitis) is 0.02 mg/ml and that against four strains of
enterovirus 70 (causative agent of acute hemorrhagic conjunctivitis) (19, 20) is 0.02 mg/ml (data not shown). The basis for
this broad-spectrum activity is (i) that the structural organization of the viral capsid and VP1 drug-binding pocket is shared
by different serotypes and (ii) that SCH 48973 has high specific
affinity for the viral capsid.
Binding kinetics and competition binding studies both support the specific interaction of SCH 48973. The number of
SCH 48973 molecules which bind to the viral capsid (44.83 6
5.08) is consistent with the results of other investigators (4, 15),
who demonstrated 40 to 60 molecules of representative inhibitors from the WIN series to be bound to human rhinovirus
type 14. The affinity constant of SCH 48973 is also within the
values described for inhibitors from the WIN series bound to
human rhinovirus type 14. Mechanistic studies (data not
shown) indicate that SCH 48973 is inhibitory early in the virus
replication cycle at the steps of viral attachment and/or uncoating, as described for a previous molecule in the series,
SCH 47802 (8). Through interactions with specific amino acids
within the VP1 cavity, capsid-binding inhibitors cause conformational changes within the VP1 cavity, the canyon (the site of
virus cell receptor interaction with the drug), and protein loops
which lie outside the canyon structure (34, 50). Comparative
studies of the perturbations caused by SCH 38057 and WIN
51711 indicate that the number and extent of conformational
changes do not correlate with antiviral activity (50). One current hypothesis is that the degree of “space filling” within the
drug-binding pocket is critical for potent antiviral activity (31,
50). The specific interactions of SCH 48973 within the drugbinding pocket will be deciphered since the cocrystallization,
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FIG. 5. Efficacy of SCH 48973 in poliovirus type 2-infected mice. Treatment
was initiated 3.5 h after infection and was continued for 21 days. SCH 48973 was
administered three times a day to achieve the total daily dose indicated. An
asterisk indicates significance compared to the placebo group at a P value of
#0.05 by the chi-square test for $5 days during the study.

X-ray diffraction, and spatial resolution of SCH 48973 in a
picornavirus have recently been accomplished (3a).
The potential activity of SCH 48973 against picornavirus
disease was determined by using poliovirus type 2-infected
mice. This model is a stringent evaluation of antiviral efficacy,
since direct intracranial inoculation of poliovirus leads to high
viral titers in target tissues, resulting in paralysis and mortality.
SCH 48973 orally administered at therapeutic levels significantly increased the survival rate for infected mice at dosages
as low as 3 mg/kg/day (1 mg/kg given three times a day). The
potency of SCH 48973 was also demonstrated by the reduction
of viral titers in the brain after therapeutic dosing. In studies in
which dosing was stopped on day 21, mice continued to survive
for an observation period of at least 6 months, indicating that
viral infection was halted in these animals (data not shown).
The overall in vivo efficacy of SCH 48973 after oral administration indicates that the compound has sufficient pharmacokinetic properties to generate inhibitory levels at sites of virus
replication.
The in vitro and in vivo profiles of SCH 48973 suggest that
it is a potential candidate for the treatment of enterovirus
infections. To date there is no approved antiviral agent for the
treatment of enterovirus infections. While respiratory illness
has been the focus of the clinical efforts in developing antipicornavirus molecules, illnesses such as aseptic meningitis (28,
36), febrile illness (9), persistent infections in agammaglobulinemic patients (26), and acute hemorrhagic conjunctivitis (20,
48) are also potential targets for therapy.

TABLE 2. Reduction of viral titers in mouse brains after
oral administration of SCH 48973
Regimena

Log10 PFU

Placebo............................................................................................. 5.6
Four times, 5 mg/kg (6 h) ............................................................. 4.4b
Four times, 5 mg/kg (24 h) ........................................................... 3.3b
a
Mice were infected with poliovirus type 2 (520 PFU). SCH 48973 was orally
administered four times at 5 mg/kg (20 mg/kg/day) beginning either 6 or 24 h
after dosing. Brains were removed on day 2 after infection, and the amount of
virus was measured by plaque assay.
b
Statistically significant efficacy compared to placebo group by Student’s t test
(P , 0.05).
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